-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Tops Q1 EPS by 42c
-
-
-
-
-
-
-
Zai Lab gets three drugs renewed on China's national reimbursement list
-
-
-
-
-
-
-
Zai Lab (ZLAB) PT Raised to $75 at Leerink Partners
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
-
-
-
-
-
-
-
BofA Securities Downgrades Zai Lab (ZLAB) to Neutral
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Announces Proposed $200M Share Offering
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Reports Q2 Loss of $0.82, Beats on Revenue
-
448,184 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

